Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit
29 Aprile 2021 - 05:45PM
Business Wire
POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH) today announced its participation at the
Mitochondria-Targeted Drug Development Summit (April 27-29).
On April 29, Sophie Bozec, PhD, Senior Vice President, R&D
Pharmacology and Scientific Communication, and Co-Founder of Poxel
is presenting a talk entitled “Mitochondrial Dysfunction in
Metabolic Diseases” during the session - Clinical Stage Molecules
Targeting Mitochondrial Mechanisms. The presentation highlights
Poxel’s scientific focus and deep expertise in mechanisms which
modulate cellular energy homeostasis and address mitochondrial
dysfunction.
Results pertaining to the mode of action for Imeglimin, PXL770
and PXL065 will be discussed. In addition, the presentation will
feature novel data related to the utility of Poxel’s AMP-kinase
(AMPK) activator and deuterium-stabilized thiazolidinedione (dTZD)
platforms for rare disorders where mitochondrial dysfunction is a
major pathogenic component.
“As a leader in the field of mitochondrial targeted
therapeutics, we appreciate the opportunity to present our science
at the Summit,” commented Dr. Bozec. “Our focus on targeting
mitochondrial dysfunction has achieved clinical validation for
efforts that are aimed at treating both Type 2 diabetes and NASH.
Our platforms also represent differentiated approaches which offer
the potential for additive or synergistic efficacy when used in
combination with other mechanisms. Moreover, we are very excited by
promising new discoveries with our molecules which indicate the
potential to treat serious and rare inherited metabolic disorders
including adrenoleukodystrophy.”
The event is dedicated to understanding mitochondrial
dysfunction & enhancing mitochondria-targeted research. To
learn more about the Summit:
https://mitochondria-targets.com/about/about-event/
About Poxel SA Poxel is a dynamic biopharmaceutical
company that uses its extensive expertise in developing innovative
drugs for metabolic diseases, with a focus on type 2 diabetes and
non-alcoholic steatohepatitis (NASH). In its mid-to-late-stage
pipeline, the Company is currently advancing three drug candidates
as well as earlier-stage opportunities. Imeglimin, Poxel’s
first-in-class lead product, targets mitochondrial dysfunction.
Poxel has a strategic partnership with Sumitomo Dainippon Pharma
for Imeglimin in Japan, China, South Korea, Taiwan and nine other
Southeast Asian countries. A Japanese new drug application (J-NDA)
is under review by the Pharmaceuticals and Medical Devices Agency
(PMDA) to request approval for the manufacturing and marketing of
Imeglimin for the treatment of type 2 diabetes. After successfully
completing a Phase 2a proof-of-concept trial for the treatment of
NASH, which met its primary endpoint and study objectives, for
PXL770, a first-in-class direct adenosine monophosphate-activated
protein kinase (AMPK) activator, Poxel plans to initiate a Phase 2b
program in the second half of 2021. PXL770 could also have the
potential to treat additional metabolic diseases. PXL065
(deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a
streamlined Phase 2 trial for the treatment of NASH. Poxel also has
additional earlier-stage programs from its AMPK activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. The Company intends to generate further growth through
strategic partnerships and pipeline development. Listed on Euronext
Paris, Poxel is headquartered in Lyon, France, and has subsidiaries
in Boston, MA, and Tokyo, Japan. For more information, please
visit: www.poxelpharma.com
In the context of the COVID-19 outbreak, which was declared a
pandemic by the World Health Organization (WHO) on March 12, 2020,
the Company is regularly reviewing the impact of the outbreak on
its business.
As of the date of this press release, and based on publicly
available information, the Company has not identified the
occurrence of any material negative effect on its business due to
the COVID-19 pandemic that remains unresolved. However, the Company
anticipates that the COVID-19 pandemic could have further material
negative impact on its business operations. The worldwide impact of
COVID-19 may notably affect the Company’s internal organization and
efficiency, particularly in countries where it operates and where
confinement measures are implemented by the authorities. In
addition, COVID-19 may impact market conditions and the Company’s
ability to seek additional funding or enter into partnerships.
Particularly, delays in the supply of drug substance or drug
products, in the initiation or the timing of results of preclinical
and/or clinical trials, as well as delays linked to the
responsiveness of regulatory authorities could occur, which could
potentially have an impact on the Company’s development programs
and partnered programs. The Company will continue to actively
monitor the situation.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005842/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78
Investor relations / Media - EU/US Trophic Communications
Stephanie May or Valeria Fisher poxel@trophic.eu +49 171 185 56 82
or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2023 a Mar 2024